CONIFER, Colo., June 28, 2005 (PRIMEZONE) -- Xpention Genetics, Inc. (OTCBB:XPNG) contracts GeneThera, Inc. (OTCBB:GTHA) to develop a molecular diagnostic cancer test for use on canines. The cancer test will use Xpention's licensed p65 technology from the University of Texas MD Anderson Cancer Center. P65 is a promising marker for the early detection of malignant tumor formation and a useful tool for monitoring therapy and remission. Levels of p65 also appear to have a direct correlation to tumor mass/size.
In addition to the immunological test which gives a yes or no result, a molecular test will be able to measure the level of expression of the p65 protein allowing its use as a confirmatory test and enabling doctors to determine the effectiveness of treatments.
GeneThera, Inc. is a molecular biotechnology company which provides genetic diagnostic solutions for the veterinary, agricultural, and health-care industries. Their proprietary diagnostic solution is based on a genetic expression assay, GEA(tm), a protocol designed to function on a highly automated Fluorogenic PCR platform. David Kittrell, CEO commented, "The contract with Genethera to develop a molecular cancer detection test for canines that is complementary to the immunological test represents the next step in our business plan to produce a comprehensive line of both diagnostic and therapeutic products based on our licensed p65 technology."
ABOUT XPENTION GENETICS, INC.:
Xpention Genetics, Inc. is a biotechnology company that was formed to develop both immunological and molecular tests for cancer detection in animals and humans as well as therapeutic vaccines and other treatment methods. Xpention Genetics, Inc. and The University of Texas MD Anderson Cancer Center signed a Patent and Technology License Agreement granting Xpention the exclusive rights to patented technology for the detection of cancer based on a tumor marker known as p65, which has been demonstrated to have elevated levels in the blood of canine and human cancer conditions.
"Safe Harbor" Statement: Certain statements in this release are "forward-looking" statements as defined in the Private Securities Litigation Reform Act of 1995. Such statements are subject to numerous risks and uncertainties. Actual results may vary significantly from the results expressed or implied in such statements. Factors that could cause actual results to materially differ from forward-looking statements include, but are not limited to, the Company's ability to meet the terms and conditions required to obtain its project financing, risks and delays associated with product development, risk of market acceptance of new products, risk of technology or product obsolescence, competitive risks, reliance on development partners and the need for additional capital.